Skip to main content
NCBI home page
Heart logoLink to Heart
. 2001 Feb;85(2):153–158. doi: 10.1136/heart.85.2.153

Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up

U Fallon 1, Y Ben-Shlomo 1, P Elwood 1, J Ubbink 1, G Smith 1
PMCID: PMC1729619  PMID: 11156664

Abstract

OBJECTIVE—Prospective assessment of the risk of coronary heart disease associated with total serum homocyst(e)ine (homocysteine) concentration.
DESIGN—Nested case-control study.
SETTING—Caerphilly and surrounding villages in south Wales, UK.
PARTICIPANTS—2290 men who participated in phase II of the study in 1984. After a mean follow up of 10 years, 312 men developed coronary heart disease and were compared with 1248 randomly selected, age frequency matched controls.
MAIN OUTCOME MEASURE—Acute myocardial infarction or death from coronary heart disease.
RESULTS—The geometric mean serum homocysteine concentration was higher in cases (12.2 µmol/l, 95% confidence interval (CI) 11.8 to 12.6 µmol/l) than in controls (11.8 µmol/l, 95% CI 11.3 to 12.5 µmol/l) (p = 0.09). There was a graded increase in the odds ratio of coronary heart disease across quintiles of the homocysteine concentration distribution compared with the first (p = 0.04), which was attenuated when adjusted for confounding variables (p = 0.4). There was a small but non-significant increase in the adjusted odds ratio of coronary heart disease per standard deviation change in the log distribution of homocysteine concentration (OR = 1.07 (95% CI .93 to 1.24), p = 0.34). Comparing the top quintile of the homocysteine concentration with the remaining 80%, the adjusted odds ratio of coronary heart disease was 1.03 (95% CI 0.73 to 1.45) (p = 0.8) and comparing the top 5% with the remaining 95% it was 1.05 (95% CI 0.56 to 1.95) (p = 0.9).
CONCLUSIONS—These findings do not support the hypothesis that a raised homocysteine concentration is a strong independent risk factor for coronary heart disease. Randomised controlled trials of homocysteine lowering treatment such as folic acid are needed before generalising the early positive results of observational studies.


Keywords: homocysteine; coronary heart disease; cohort

Full Text

The Full Text of this article is available as a PDF (117.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfthan G., Aro A., Gey K. F. Plasma homocysteine and cardiovascular disease mortality. Lancet. 1997 Feb 8;349(9049):397–397. doi: 10.1016/S0140-6736(97)80014-1. [DOI] [PubMed] [Google Scholar]
  2. Alfthan G., Pekkanen J., Jauhiainen M., Pitkäniemi J., Karvonen M., Tuomilehto J., Salonen J. T., Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994 Mar;106(1):9–19. doi: 10.1016/0021-9150(94)90078-7. [DOI] [PubMed] [Google Scholar]
  3. Arnesen E., Refsum H., Bønaa K. H., Ueland P. M., Førde O. H., Nordrehaug J. E. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995 Aug;24(4):704–709. doi: 10.1093/ije/24.4.704. [DOI] [PubMed] [Google Scholar]
  4. Bostom A. G., Silbershatz H., Rosenberg I. H., Selhub J., D'Agostino R. B., Wolf P. A., Jacques P. F., Wilson P. W. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999 May 24;159(10):1077–1080. doi: 10.1001/archinte.159.10.1077. [DOI] [PubMed] [Google Scholar]
  5. Bots M. L., Launer L. J., Lindemans J., Hoes A. W., Hofman A., Witteman J. C., Koudstaal P. J., Grobbee D. E. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999 Jan 11;159(1):38–44. doi: 10.1001/archinte.159.1.38. [DOI] [PubMed] [Google Scholar]
  6. Boushey C. J., Beresford S. A., Omenn G. S., Motulsky A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4;274(13):1049–1057. doi: 10.1001/jama.1995.03530130055028. [DOI] [PubMed] [Google Scholar]
  7. Chasan-Taber L., Selhub J., Rosenberg I. H., Malinow M. R., Terry P., Tishler P. V., Willett W., Hennekens C. H., Stampfer M. J. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996 Apr;15(2):136–143. doi: 10.1080/07315724.1996.10718578. [DOI] [PubMed] [Google Scholar]
  8. Christen W. G., Ajani U. A., Glynn R. J., Hennekens C. H. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med. 2000 Feb 28;160(4):422–434. doi: 10.1001/archinte.160.4.422. [DOI] [PubMed] [Google Scholar]
  9. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155. doi: 10.1056/NEJM199104253241701. [DOI] [PubMed] [Google Scholar]
  10. Danesh J., Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998 Aug;5(4):229–232. [PubMed] [Google Scholar]
  11. Egerton W., Silberberg J., Crooks R., Ray C., Xie L., Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 1996 Apr 1;77(9):759–761. doi: 10.1016/s0002-9149(97)89213-2. [DOI] [PubMed] [Google Scholar]
  12. Eikelboom J. W., Lonn E., Genest J., Jr, Hankey G., Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999 Sep 7;131(5):363–375. doi: 10.7326/0003-4819-131-5-199909070-00008. [DOI] [PubMed] [Google Scholar]
  13. Evans R. W., Shaten B. J., Hempel J. D., Cutler J. A., Kuller L. H. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):1947–1953. doi: 10.1161/01.atv.17.10.1947. [DOI] [PubMed] [Google Scholar]
  14. Folsom A. R., Nieto F. J., McGovern P. G., Tsai M. Y., Malinow M. R., Eckfeldt J. H., Hess D. L., Davis C. E. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998 Jul 21;98(3):204–210. doi: 10.1161/01.cir.98.3.204. [DOI] [PubMed] [Google Scholar]
  15. Graham I. M., Daly L. E., Refsum H. M., Robinson K., Brattström L. E., Ueland P. M., Palma-Reis R. J., Boers G. H., Sheahan R. G., Israelsson B. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997 Jun 11;277(22):1775–1781. doi: 10.1001/jama.1997.03540460039030. [DOI] [PubMed] [Google Scholar]
  16. Hankey G. J., Eikelboom J. W. Homocysteine and vascular disease. Lancet. 1999 Jul 31;354(9176):407–413. doi: 10.1016/S0140-6736(98)11058-9. [DOI] [PubMed] [Google Scholar]
  17. Hoogeveen E. K., Kostense P. J., Jakobs C., Dekker J. M., Nijpels G., Heine R. J., Bouter L. M., Stehouwer C. D. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation. 2000 Apr 4;101(13):1506–1511. doi: 10.1161/01.cir.101.13.1506. [DOI] [PubMed] [Google Scholar]
  18. Israelsson B., Brattström L., Refsum H. Homocysteine in frozen plasma samples. A short cut to establish hyperhomocysteinaemia as a risk factor for arteriosclerosis? Scand J Clin Lab Invest. 1993 Aug;53(5):465–469. doi: 10.3109/00365519309092541. [DOI] [PubMed] [Google Scholar]
  19. Lindgren A., Brattström L., Norrving B., Hultberg B., Andersson A., Johansson B. B. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995 May;26(5):795–800. doi: 10.1161/01.str.26.5.795. [DOI] [PubMed] [Google Scholar]
  20. McCully K. S. Homocysteine and vascular disease. Nat Med. 1996 Apr;2(4):386–389. doi: 10.1038/nm0496-386. [DOI] [PubMed] [Google Scholar]
  21. Nygård O., Vollset S. E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J. E., Ueland M., Kvåle G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995 Nov 15;274(19):1526–1533. doi: 10.1001/jama.1995.03530190040032. [DOI] [PubMed] [Google Scholar]
  22. Refsum H., Ueland P. M., Nygård O., Vollset S. E. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62. doi: 10.1146/annurev.med.49.1.31. [DOI] [PubMed] [Google Scholar]
  23. Stampfer M. J., Malinow M. R., Willett W. C., Newcomer L. M., Upson B., Ullmann D., Tishler P. V., Hennekens C. H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877–881. [PubMed] [Google Scholar]
  24. Ubbink J. B., Fehily A. M., Pickering J., Elwood P. C., Vermaak W. J. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis. 1998 Oct;140(2):349–356. doi: 10.1016/s0021-9150(98)00139-7. [DOI] [PubMed] [Google Scholar]
  25. Ubbink J. B., Hayward Vermaak W. J., Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991 Apr 19;565(1-2):441–446. doi: 10.1016/0378-4347(91)80407-4. [DOI] [PubMed] [Google Scholar]
  26. Verhoef P., Hennekens C. H., Allen R. H., Stabler S. P., Willett W. C., Stampfer M. J. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 1997 Mar 15;79(6):799–801. doi: 10.1016/s0002-9149(96)00874-0. [DOI] [PubMed] [Google Scholar]
  27. Verhoef P., Hennekens C. H., Malinow M. R., Kok F. J., Willett W. C., Stampfer M. J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994 Oct;25(10):1924–1930. doi: 10.1161/01.str.25.10.1924. [DOI] [PubMed] [Google Scholar]
  28. Wald N. J., Watt H. C., Law M. R., Weir D. G., McPartlin J., Scott J. M. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998 Apr 27;158(8):862–867. doi: 10.1001/archinte.158.8.862. [DOI] [PubMed] [Google Scholar]
  29. Ward M., McNulty H., McPartlin J., Strain J. J., Weir D. G., Scott J. M. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM. 1997 Aug;90(8):519–524. doi: 10.1093/qjmed/90.8.519. [DOI] [PubMed] [Google Scholar]
  30. Whincup P. H., Refsum H., Perry I. J., Morris R., Walker M., Lennon L., Thomson A., Ueland P. M., Ebrahim S. B. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart. 1999 Oct;82(4):448–454. doi: 10.1136/hrt.82.4.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yarnell J. W., Baker I. A., Sweetnam P. M., Bainton D., O'Brien J. R., Whitehead P. J., Elwood P. C. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation. 1991 Mar;83(3):836–844. doi: 10.1161/01.cir.83.3.836. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES